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Abstract
Background: The Bradykinesia Akinesia Incoordination (BRAIN) test is a computer keyboard-tapping task that was
developed for use in assessing the effect of symptomatic treatment on motor function in Parkinson’s disease (PD). An online
version has now been designed for use in a wider clinical context and the research setting.
Methods: Validation of the online BRAIN test was undertaken in 58 patients with Parkinson’s disease (PD) and 93 age-
matched, non-neurological controls. Kinesia scores (KS30, number of key taps in 30 seconds), akinesia times (AT30, mean
dwell time on each key in milliseconds), incoordination scores (IS30, variance of travelling time between key presses) and
dysmetria scores (DS30, accuracy of key presses) were compared between groups. These parameters were correlated
against total motor scores and sub-scores from the Unified Parkinson’s Disease Rating Scale (UPDRS).
Results: Mean KS30, AT30 and IS30 were significantly different between PD patients and controls (p#0.0001). Sensitivity for
85% specificity was 50% for KS30, 40% for AT30 and 29% for IS30. KS30, AT30 and IS30 correlated significantly with UPDRS
total motor scores (r =20.53, r = 0.27 and r = 0.28 respectively) and motor UPDRS sub-scores. The reliability of KS30, AT30
and DS30 was good on repeated testing.
Conclusions: The BRAIN test is a reliable, convenient test of upper limb motor function that can be used routinely in the
outpatient clinic, at home and in clinical trials. In addition, it can be used as an objective longitudinal measurement of
emerging motor dysfunction for the prediction of PD in at-risk cohorts.
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Introduction
The Bradykinesia Akinesia Incoordination (BRAIN) test has
been validated as a sensitive software tool for detecting signs of
neurological disease, including Parkinson’s disease (PD) and
cerebellar dysfunction [1]. Based on the alternate finger tapping
test, it has also been compared against the Unified Parkinson’s
Disease Rating Scale (UPDRS) and other PD severity scales [2].
Sequential finger tapping is part of the routine neurological
examination for the detection of bradykinesia defined as ‘slowness
of initiation of voluntary movement with progressive reduction in
speed and amplitude of repetitive action’ [3]. Bradykinesia is tested
as part of the motor section of the UPDRS, but severity of the
sequence effect and the frequency of motor arrests are not
specifically measured.
The traditional alternate finger tap test, in which the patient is
observed tapping two mounted counters 15 cm apart as fast as
possible has been used for many years to measure response to
symptomatic drug treatment [4]. The BRAIN test replicates this
test using a computer screen and keyboard and can provide
additional information relating to the nature of the motor
handicap in different neurological disorders. The user must
alternately tap the ‘S’ and the ‘;’ keys as rapidly and as accurately
as they can over a 30-second time period.
The original version of the BRAIN test was programmed to run
in MS-DOS mode on an IBM-compatible personal computer [1].
We have developed a modified version that can run with all
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standard internet browsers. The patient or research volunteer
completes the test online and the results are uploaded to a secure
database for storage and analysis. Preliminary results on a small
group of PD patients have already been reported [5]. In the
present report, we have addressed the following issues:
1) The normal range of scores in healthy individuals and what
influences these,
2) The difference in scores between PD patients and healthy
individuals,
3) The reliability of the BRAIN test and its utility in repeat
measurement.
Methods
Ethics statement: All participants gave written informed consent
via the BRAIN test website. The web-based consent form lists
relevant consent statements and each statement has a check box.
Participants must check each box before clicking the submit
button on screen. The Queen Square Research Ethics Committee
approved the entire study and the specific method of obtaining
written consent.
Patients who fulfilled the Queen Square Brain Bank for
Neurological Disorders criteria for the clinical diagnosis of PD
and age-matched non-neurological controls were recruited from
the outpatient department at the Royal London Hospital and the
National Hospital for Neurology and Neurosurgery.3
Participants undertook the test seated at a desktop computer
and keyboard. They followed on-screen test instructions and
received no assistance during the test. Participants were allowed to
choose which hand was tested first in acknowledgement of the fact
that future use may frequently be unobserved. Each participant
undertook two tests (one for each hand). Preliminary study
established that a 30 second time period gave adequate
Table 1. Demographic Information.
PD Controls
Number 58 93
Mean age (SD) 63.0 (10.6) 60.5 (13.1)
Gender
- Male 37 (64%) 32 (34.4%)
- Female 21 (36%) 61 (65.6%)
Education
- Primary 2 (4%) 4 (4%)
- Secondary 35 (60%) 46 (50%)
- Higher 7 (12%) 19 (20%)
- Further 14 (24%) 24 (26%)
Occupation
- Professional 10 (17%) 26 (28%)
- Non-professional skilled 23 (40%) 37 (40%)
- Non-professional non-skilled 10 (17%) 22 (24%)
- Retired with no additional information 15 (26%) 8 (8%)
Handedness
- Right 54 (93%) 81 (87%)
- Left 3 (5%) 11 (12%)
- Ambidextrous 1 (2%) 1 (1%)
Mean years since diagnosis (SD) 8.4 (6.6) –
On/Off*
- On 38 (66%) –
- Off 20 (34%) –
Levodopa
- Yes 52 (90%) –
- No 6 (10%) –
Mean minutes since levodopa dose (SD) 186 (133) –
Hoehn-Yahr stage
- Stage 1 11 (19%) –
- Stage 2 34 (59%) –
- Stage 3 13 (22%) –
PD, Parkinson’s disease. SD, standard deviation.
*On/off in this table refers to the question in the MDS-UPDRS, which asks whether participants could feel the effects of medication at the time of examination. Note it
does not indicate that all participants had motor fluctuations.
doi:10.1371/journal.pone.0096260.t001
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information and would lead to greater compliance than testing for
one minute [5]. Demographic data were recorded for all
participants including gender, year of birth, level of education
and self-reported hand dominance. For controls, additional co-
morbidity information was recorded. For patients with PD,
current medication, time of last dose of levodopa, number of
years since diagnosis and Hoehn-Yahr stage were recorded.
Patients with PD were examined using the motor section of the
Movement Disorders Society (MDS) UPDRS by a trained
clinician (AJN). The MDS-UPDRS includes a question about
Figure 1. Comparison of KS30, AT30 and IS30 in patients with PD and controls (average of score from each hand). Distribution of KS30
(mean and standard deviation), (b) AT30 and (c) IS30 (medians and interquartile ranges). For IS30, 7 data points were out of the axis range. Receiver
operating characteristic (ROC) curves for (d) KS30, (e) AT30 and (f) IS30.
doi:10.1371/journal.pone.0096260.g001
Table 3. Comparison of KS30, AT30, IS30, DS30 in all* PD patients versus controls.
Mean KS30 (95% CI) Median AT30 (IQR) Median IS30 (IQR) Median DS30 (IQR)
PD 44.2 (40.9, 47.5) 138.7 (100.5, 221.0) 13813 (8744, 29857) 1.042 (1.014, 1.147)
Controls 60.3 (57.6, 63.0) 97.3 (80.7, 131.2) 6758 (4030, 16664) 1.044 (1.013, 1.110)
p-value ,0.0001 ,0.0001 0.0003 0.45
KS30 Sensitivity AT30 Sensitivity IS30 Sensitivity
(cut-off) (cut-off) (cut-off)
Specificity 90% 44.8%* (42.5) 31.0%* (183) 24.1%* (29954) -
Specificity 85% 50.0% (46.0) 39.7% (156) 29.3% (23527) -
Specificity 80% 56.9% (48.3) 43.1% (149) 36.2% (18527) -
PD, Parkinson’s disease; KS30, kinesia score; AT30, akinesia time; IS30, incoordination score; DS30, dysmetria score; CI, confidence interval; IQR, interquartile range.
*If analyses were limited to include only patients that were ‘Off’ (n =20) the sensitivities (and cut-off) for 90% specificity for KS30, AT30 and IS30
were 65% (43), 50% (175) and 55% (29373) respectively.
doi:10.1371/journal.pone.0096260.t003
The BRAIN Test
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the clinical state of patients on medication. ‘On’ is the typical
functional state when patients are receiving medication and have a
good response and ‘Off’ is the typical functional state when
patients have a poor response in spite of taking medications. These
definitions of ‘On’ and ‘Off’ were recorded for each patient.
For reliability testing, 17 of the controls were asked to repeat the
test multiple times for each hand. This had the secondary
advantage of being able to investigate the possibility of a learning
effect. Due to the tendency of motor features of PD to change in
relation to medication and possible time of day, PD patients were
not included in tests measuring reliability. However, six patients
with PD and known motor fluctuations were invited to undertake
the test on several occasions during the day, before and after
medication in order to evaluate the BRAIN test in monitoring
motor fluctuations.
The BRAIN test reports four variables calculated from raw data
generated from key taps: kinesia score (KS30), the number of key
taps in 30 seconds; akinesia time (AT30), the mean dwell time on
each key in milliseconds (msec); dysmetria score (DS30), a
weighted index using the number of incorrectly hit keys scored
in a target fashion (1 point for the correct key, 2 points for
immediately adjacent keys and 3 for other keys) then divided by
the total number of key taps (i.e. if all keys are hit correctly, the
score should be 1.0); and incoordination (or arrhythmia) score
(IS30), the variance of the time interval in msec between
keystrokes.
Descriptive statistics were calculated for all four variables. For
continuous variables, means were reported if the data were
normally distributed (assessed using the Shapiro-Wilks test) and
medians were reported if not normally distributed. Within-group
(PD or control) comparisons were performed using the paired t-
test for normal distributed data or Wilcoxon-signed rank test for
non-normally distributed data. Between-group comparisons were
made using the unpaired t-test or Wilcoxon rank sum test. The
sensitivity and specificity of test parameters separately and together
were determined using logistic regression and receiver operated
characteristic (ROC) curves. Associations between UPDRS and
BRAIN test parameters were estimated using Spearman’s rank
correlation coefficient for non-normally distributed data. Coeffi-
cients of variation were calculated to determine reliability of test
parameters in control subjects undertaking the test multiple times.
The pre-determined significance level for all calculations was
p= 0.05. All analyses were performed using Stata version 12 and
GraphPad Prism version 6 for Mac.
Results
There were 58 PD patients and 93 non-neurological controls
included in the main analysis (for group characteristics see
Table 1). One PD patient and one control subject were
ambidextrous and were excluded from analyses that compared
BRAIN test scores between the dominant and non-dominant
hands. One PD patient tested in the clinic had incomplete
UPDRS data and was excluded from those specific analyses.
Associations of KS30, AT30, IS30 and DS30 with age, gender,
education, occupation and co-morbidities were undertaken in
controls (see Table 2). KS30 decreased by 0.66 points, AT30
increased by 1.35% and IS30 increased by 4.7% per year of age
(all p,0.001). No significant correlation between DS30 and age
was seen. Lower levels of education tended to give poorer scores
for KS30 and AT30, and gave significantly poorer scores for IS30
and DS30. Analyses considering occupation showed that having a
professional occupation gave significantly better KS30 scores, but
there were no significant differences in the other parameters for
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different occupations. The presence of comorbidity did little to
affect test results except for the finding that having any
comorbidity worsened IS30 compared to those with no comor-
bidity and KS30 was non-significantly lower in those with
depression. There was no significant effect of handedness and
parameters were similar between males and females, except that
females were significantly more accurate than males (improved
DS30).
When PD patients (n = 58) and controls (n = 93) were compared
using averages of the scores from each hand; KS30, AT30 and
IS30 discriminated between groups, but DS30 did not (see Table 3
and Figure 1). KS30 showed the best discrimination between PD
and controls with sensitivities of 45%, 50% and 57% for
specificities of 90%, 85%, and 80% respectively. Corresponding
sensitivities were 31%, 40% and 43% for AT30 and 24%, 29%
and 36% for IS30. The addition of AT30 or IS30 to KS30 did not
improve discrimination compared with KS30 alone (assessed by
multivariate logistic regression). When patients that were ‘On’
were excluded and patients that were ‘Off’ (n = 20) were compared
to controls, the sensitivities for 90% specificity were 65%, 50% and
55% for KS30, AT30 and IS30 respectively. Subjects tested whilst
‘On’ had better KS30 scores than subjects who were tested whilst
‘Off’ (47.8 and 37.3 respectively, p = 0.002). IS30 scores were also
significantly better in those that were ‘On’ (11682 and 29568
respectively, p = 0.007) and there was trend for improvement in
AT30 (125.1 and 172.6 respectively, p = 0.27).
Hands were compared in patients and controls (see Table 4). In
both the dominant and non-dominant hands tests mean KS30 was
significantly lower in PD patients than controls, and AT30 and
IS30 were significantly higher. In patients and controls the
dominant hand significantly out-performed the non-dominant
hand for KS30 and AT30, but not for IS30 or DS30.
BRAIN test scores in PD patients only were compared to total
motor UPDRS scores and sub-scores (see Figure 2) using averages
of the scores from each hand. KS30 showed a moderate inverse
correlation with total motor UPDRS (Spearman’s r =20.53, p,
0.0001). AT30 and IS30 showed weak but significant positive
correlations with total motor UPDRS (Spearman’s r = 0.27,
p = 0.03 and r = 0.28, p = 0.03 respectively). DS30 showed no
correlation. Further correlations were undertaken with sub-
sections of the UPDRS including upper limb tone, finger tapping,
hand opening and closing, and pronation-supination (see Table 5).
In PD patients there was a difference of borderline significance
with lower KS30 in the more affected hand when compared to the
less affected hand (mean KS30 42.5 v 44.8, p = 0.053). There was
no difference in AT30, IS30 and DS30 between the two hands
(median AT30 134 v 128, p = 0.350; median IS30 12604 v 12048,
p = 0.421, median DS30 1.034 v 1.051, p = 0.569). Duration of
PD in years did not correlate with any of the four parameters (data
not shown).
Seventeen of the controls repeated the BRAIN test five times for
each hand to estimate the reliability of KS30, AT30, IS30 and
DS30. The coefficient of variation for KS30 was 6.0%, for AT30
was 7.3%, and for DS30 was 3.4%. IS30 had a high coefficient of
variation reflecting the fact that pauses in the test (even in control
subjects) magnify the variance of travelling time significantly,
decreasing the reliability of IS30 overall. There was a mild
learning effect that saw KS30 increase by 1.2 taps per attempt
Figure 2. Correlation of (a) KS30, (b) AT30, (c) IS30 but not (d) DS30 with total motor UPDRS in patients with PD.
doi:10.1371/journal.pone.0096260.g002
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(p = 0.002) but no learning effect for AT30 (decrease of 1.0 ms per
attempt, p = 0.203) or for IS30 and DS30 (p values derived from
multilevel mixed effects linear regression).
Finally, using KS30 and AT30 the effects of medication were
assessed in a small number of PD patients with predictable motor
fluctuations (see Figure 3) and also in patients with unpredictable
fluctuations (see Fure 4).
Discussion
The BRAIN test has previously been shown to differentiate
individuals with PD from healthy controls and also to correlate
with PD severity measured by disease-specific rating scales [1,2].
The results of these two studies, in which the original version of the
test was performed on a single laptop computer under defined
conditions, have been replicated here with this new online version
of the test, allowing it to be administered without direct
observation or investigator input. It can be accessed remotely
from wherever there is an internet connection and a computer
(laptop or desktop) keyboard.
In PD patients, KS30 correlated significantly with total motor
UPDRS score, and limb specific sub-scores, as clinical indicators
of motor disease severity. AT30 and IS30 also correlated
significantly, albeit less strongly than KS30, with the total motor
UPDRS score and some of the limb specific sub-scores.
Our data for PD and non-neurologic controls shows wide intra-
group variability and yet the differences between KS30, AT30 and
IS30 are highly significant and of clinically relevant magnitude,
enabling cut-offs for sensitivity and specificity to be determined.
We present results to optimize specificity, with resulting moderate
to low sensitivity, thereby reducing the false-positive rate in
acknowledgment that the test will often be performed remotely. Of
course sensitivity and specificity operate on a continuum and
much higher sensitivity can be achieved if the cut-offs are altered
to accept a higher false positive rate.
Age clearly affected most of BRAIN test parameters and should
be taken in consideration in future studies using the test. Education
also influenced parameters perhaps reflecting an effect of
computer literacy. However, this was not further reflected when
examining occupation, with which strong relationships could not
be found. This perhaps reflects widespread uptake of computers
regardless of whether use is work-related or recreational. Patients
that were tested in whilst ‘On’ performed better than those that
were ‘Off’. When PD patients that were ‘Off’ were compared to
controls the discriminative ability of KS30, AT30 and IS30
improved significantly. Comparison of most and least affected
sides in PD patients only showed trends for poorer scores on the
most affected side, perhaps reflecting bilateral involvement in 80%
of the patient group (Hoehn and Yahr score 2 & 3).
Whilst not seemingly useful for differentiating PD from healthy
controls, the dysmetria score (DS30) does provides a useful
reference for judging whether tests have been completed properly,
which is particularly valuable for remote testing. For example, the
mean KS30 in controls is 60.3 and has a standard deviation of
13.1. Using three standard deviations as a cut-off, it is unlikely that
an individual can exceed 100 alternate taps in 30 seconds without
a dramatic loss of accuracy as reflected by the DS30. Occasionally
very high scores have been seen in remote tests, such as those
performed in the PREDICT-PD study (described further below),
with perfect or near-perfect accuracy (e.g. KS30 of 200 and DS30
of 1.0) [6]. This suggests that the subject is using two hands to hit
the keys and is not alternating between keys with a single hand,
and such results should be excluded from analyses.T
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Some highly specialized tools have been developed that can
accurately measure the specific motor deficit that occurs in PD and
some have the capacity to differentiate the sequential tapping
abnormalities in PD (true bradykinesia) from that seen in
progressive supranuclear palsy and atypical tremors [7–9]. When
compared to such tools, the BRAIN test appears fairly crude, but
Figure 3. Examples of repeat tests in 3 PD patients with predictable motor fluctuation. Arrows denote times at which levodopa was taken.
doi:10.1371/journal.pone.0096260.g003
Figure 4. Further examples of repeat tests in 3 patients with predictable fluctuation (patient 4) and unpredictable motor
fluctuation (patients 5 and 6). Arrows denote times at which levodopa was taken.
doi:10.1371/journal.pone.0096260.g004
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these specialist tests, whilst fulfilling a valuable role in research, are
not currently applicable in routine clinical practice. Further study
using the BRAIN test will now concentrate on whether a sequence
effect can be demonstrated in patients that are ‘Off’ medication
following a period of drug withdrawal and also studying greater
numbers of patients with motor fluctuations in their ‘On’ and ‘Off’
phases, since the current study does not address these important
aspects fully.
One criticism leveled at the BRAIN test during preliminary
testing was that not all keyboards have identical characters,
particularly outside the US and UK. Furthermore, the position of
the ‘S’ and ‘;’ keys on the keyboard can vary between countries.
These keys were originally chosen because they are 15 cm apart on
a US/UK English standard desktop computer keyboard and most
laptop computers. If one considers a standard keyboard divided in
two halves by an imaginary line down the center, then these keys
occupy a central position on their respective sides. In countries
where US/UK English keyboards are not standard, the test can
still be used with the keys that correspond to the position of ‘S’ and
‘;’ and has been implemented successfully by groups in Italy,
Norway and the Netherlands (personal communications).
During testing we have found no evidence that use of different
keyboards results in significant differences in results between
subjects. However, use on tablet computers may be limited by the
availability of the ‘;’ key and the different nature of touching a
screen rather than pressing a key. As such we do not advise use of
the BRAIN test on tablet computers or smart phones. In addition,
use of sterile covers for keyboards in clinical settings may impair
key presses. This might conceivably result in loss of accuracy
(DS30) but is unlikely to affect the other three parameters (KS30,
AT30 and IS30).
Undoubtedly the greatest value of the BRAIN test in established
PD may come in the longitudinal monitoring of individual patients
throughout the duration of their disease, including response to
treatment and monitoring motor fluctuations. Repeat testing in
controls suggests good reliability for three of the four parameters
and only a minimal learning effect. In this analysis, control subjects
repeated the tapping tests back-to-back and the fact that only a
minimal learning effect was noted makes it unlikely that
improvements due to learning would be seen were serial tests
separated by days or weeks.
The BRAIN test has been successfully implemented as a motor
assessment in our longitudinal online Parkinson’s risk study,
PREDICT-PD, which began recruiting participants in April 2011
[6]. Individuals under follow-up in this study undertake the
BRAIN test on an annual basis. Higher and lower risk groups were
characterized on the basis of early non-motor symptoms for PD
and recognized risk factors. When the 100 participants with the
highest risk estimates where compared to 100 with lowest risk
scores, significant differences in KS30 where found [6]. Other
predictive and high-risk cohorts for PD have concentrated on early
non-motor features and imaging abnormalities to ascribe risk of
future conversion to PD [10,11]. To our knowledge only one
longitudinal study of PD risk has employed an objective
computerized test. In the Honolulu Asia Ageing Study (HAAS)
it was demonstrated that men in the slowest tertile of a reaction
time test were significantly more likely to have Lewy body
pathology at post mortem [12]. Postuma and colleagues have
followed up a large cohort of patients with REM sleep behavior
disorder (RBD), which is a strong risk factor for PD [13]. They
demonstrated that motor deterioration could be measured for
approximately 4-8 years across a number of motor domains
(including alternate finger tapping) prior to the diagnosis of PD.
The premotor period has been estimated to last between 5–15
years prior to the diagnosis of PD [14]. We prefer the term pre-
diagnostic PD in this context; given the stringent motor criteria
that must be met for a clinical diagnosis (including demonstration
of a sequence effect), it seems likely that subtle motor dysfunction
must be present at an earlier stage [15,16].
The online BRAIN test represents a simple, validated, objective
tool to longitudinally monitor motor function not only in
established PD but also in studies seeking to identify those at high
risk of future PD. The BRAIN test can be accessed at www.
braintaptest.com. Tokens for individual use can be requested by
clinicians and researchers via the website.
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